Page last updated: 2024-11-02

oxidopamine and Pulmonary Hypertension

oxidopamine has been researched along with Pulmonary Hypertension in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tucker, A1
Bryant, SE1
Frost, HH1
Migally, N1

Other Studies

1 other study available for oxidopamine and Pulmonary Hypertension

ArticleYear
Chemical sympathectomy and serotonin inhibition reduce monocrotaline-induced right ventricular hypertrophy in rats.
    Canadian journal of physiology and pharmacology, 1983, Volume: 61, Issue:4

    Topics: Animals; Cardiomegaly; Fenclonine; Hydroxydopamines; Hypertension, Pulmonary; Lung; Male; Monocrotal

1983